# A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

> **NCT05419492** · PHASE1,PHASE2 · RECRUITING · sponsor: **Encoded Therapeutics** · enrollment: 47 (estimated)

## Conditions studied

- Dravet Syndrome

## Interventions

- **DRUG:** ETX101

## Key facts

- **NCT ID:** NCT05419492
- **Lead sponsor:** Encoded Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-14
- **Primary completion:** 2028-01
- **Final completion:** 2033-01
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05419492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05419492, "A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05419492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*